Capricor Therapeutics (CAPR) Misses Q4 EPS by 11c

Capricor Therapeutics (NASDAQ: CAPR) reported Q4 EPS of ($0.62), $0.11 worse than the analyst estimate of ($0.51).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• X Financial (XYF) Tops Q2 EPS by 438c
• Global Payments launches Genius World event in Las Vegas
• Laser Photonics unit wins $1.05M pharma tablet drilling order